Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Advanced CKD stages were associated with lower serum klotho levels (P < 0.001, P for linear trend< 0.001).The clinical characteristics of the study subjects at enrollment stratified by serum klotho levelCharacteristicsTotal (N = 2101)Klotho groupsP-valueP for trend1st quartile (n = 524) (99 to 419 pg/mL)2nd quartile (n = 528) (420 to 536 pg/mL)3rd quartile (n = 523) (537 to 666 pg/mL)4th quartile (n = 526) (667 to 3641 pg/mL)Age (mean ± SD)53.6 ± 12.254.0 ± 11.854.6 ± 11.953.5 ± 12.252.2 ± 12.50.0150.007Gender, male, n (%)1284 (61.1)330 (63.0)319 (60.4)317 (60.6)318 (60.5)0.7950.440BMI (kg/m2)24.5 ± 3.424.8 ± 3.524.6 ± 3.224.5 ± 3.424.2 ± 3.30.0360.005DM, n (%)712 (33.9)171 (32.6)192 (36.4)172 (32.9)177 (33.7)0.5600.962HTN, n (%)2020 (96.1)507 (96.8)517 (97.9)501 (95.8)495 (94.1)0.0110.007SBP (mmHg)128.5 ± 16.4129.3 ± 16.1128.5 ± 16.6127.9 ± 16.9128.5 ± 16.10.5990.370DBP (mmHg)76.9 ± 11.276.7 ± 11.877.0 ± 11.176.6 ± 11.277.2 ± 10.50.7860.667ACEi or ARB, yes, n (%)1795 (85.6)458 (87.4)461 (87.5)442 (84.7)434 (82.7)0.0750.013eGFR (ml/min/1.73m2)53.0 ± 30.748.2 ± 28.647.6 ± 27.854.6 ± 31.661.7 ± 32.5< 0.001< 0.001Hemoglobin (g/dL)12.8 ± 2.012.6 ± 1.912.6 ± 2.012.9 ± 2.013.3 ± 2.10.001< 0.001Uric acid (mg/dL)7.0 ± 1.97.4 ± 2.07.2 ± 1.96.9 ± 1.96.6 ± 1.8< 0.001< 0.001Albumin (g/dL)4.2 ± 0.44.1 ± 0.44.2 ± 0.44.2 ± 0.44.2 ± 0.50.3160.068Total cholesterol (mg/dL)174.3 ± 39.4174.0 ± 39.3172.0 ± 38.0172.5 ± 40.3178.8 ± 39.60.0210.053CRP, median, (Q1, Q3) (mg/dL)0.06 (0.02, 0.17)0.08 (0.03, 0.20)0.06 (0.03, 0.16)0.06 (0.02, 0.16)0.05 (0.02, 0.13)< 0.001< 0.001Phosphorus (mg/dL)3.7 ± 0.73.8 ± 0.73.7 ± 0.73.7 ± 0.73.6 ± 0.60.0040.001Corrected Ca (mg/dL)9.0 ± 0.49.0 ± 0.49.0 ± 0.59.0 ± 0.48.9 ± 0.40.5050.530Klotho, median (Q1, Q3) (pg/mL)536 (420, 667)335 (269, 383)479 (449, 505)593 (562, 626)788 (714, 913)< 0.001< 0.00125(OH)VitD, median (Q1, Q3) (ng/mL)16.5 (12.7, 21.3)16.7(13.5, 21.7)16.6(13.1, 21.2)16.4(12.6, 21.3)16.1(12.1, 21.0)0.0400.0051,25(OH)2VitD, median (Q1, Q3) (pg/mL)25.4 (20.1, 33.7)26.4 (20.1, 36.2)24.6 (19.1, 31.6)24.3 (19.4, 32.5)26.6 (21.4, 34.4)< 0.0010.599iPTH, median (Q1, Q3) (pg/mL)51.5 (33.2, 84.0)55.0 (35.0, 86.1)53.0 (34.5, 88.8)52.6 (33.9, 86.8)46.3 (30.2, 74.8)0.0050.003C-terminal FGF23, median (Q1, Q3) (RU/mL)17.9 (0.4, 31.3)18.5 (0.3, 30.2)19.0 (1.0, 32.3)18.6 (0.8, 31.5)10.4 (0.2, 31.4)0.0940.419UACR, > 300 mg/g, n (%)884 (49.9)217 (52.3)255 (56.0)205 (45.5)207 (45.9)< 0.001< 0.001LVMI, median (Q1, Q3) (g/m2.7)40.3 (33.8, 48.6)41.3 (34.7, 50.2)40.9 (34.4, 49.2)39.5 (33.5, 49.3)39.6 (32.5, 46.7)< 0.001< 0.001LVH, n (%)509 (24.8)145 (28.3)139 (27.0)128 (24.8)97 (19.2)0.0040.001LV geometry, n (%)0.0840.006 Normal1248 (60.9)303 (59.1)304 (59.0)316 (61.2)325 (64.2) Concentric remodeling293 (14.3)65 (12.7)72 (14.0)72 (14.0)84 (16.6) Eccentric LVH254 (12.4)76 (14.8)70 (13.6)60 (11.6)48 (9.5) Concentric LVH255 (12.4)69 (13.5)69 (13.4)68 (13.2)49 (9.7)baPWV (cm/s)1534 ± 3441552 ± 3481552 ± 3221527 ± 3571507 ± 3470.1270.024ahfPWV (cm/s)1018 ± 2741053 ± 3001028 ± 2571005 ± 277989 ± 2580.0220.002AAC ≥ 1, n (%)703 (35.0)172 (35.0)194 (38.0)183 (36.6)154 (30.6)0.0790.127CACS > 100, n (%)498 (24.6)133 (26.2)131 (25.7)121 (24.0)113 (22.6)0.5280.143LVEF < 50%30 (1.5)8 (1.5)5 (1.0)7 (1.3)10 (2.0)0.6070.497E/E’ > 15176 (8.6)46 (9.0)47 (9.1)42 (8.2)41 (8.1)0.9230.536a1243 patients measured hfPWV (vs. 1907 patients measured baPWV) at the study enrollmentSD, standard deviation; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate by CKD-EPI creatinine equation; CRP, C-reactive protein; Ca, calcium; 25(OH)VitD, 25-hydroxy vitamin D; 1,25(OH)2VitD, 1,25-hydroxy vitamin D; iPTH, intact parathyroid hormone; FGF23, fibroblast growth factor 23; UACR, random urine albumin-creatinine ratio; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; baPWV, brachial-to-ankle pulse wave velocity; hfPWV, heart-to-femoral pulse wave velocity; AAC, Abdominal aorta calcification; CACS, coronary artery calcium score; LVEF, left ventricular ejection fraction; E/E’, ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E’)Serum klotho levels across CKD stages.
Source: Demographic and baseline clinical characteristics of participants. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Twelve patients were excluded as extreme values (serum klotho either lower than detectable range or above 6000 pg/mL).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study
Study design awaiting verification · BMC Nephrology · 2018
Original publication title
The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study
© The Author(s). 2018
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Klotho, a protein linked to aging, has emerged as a pivotal player in mineral bone metabolism and might explain the relationship between chronic kidney disease (CKD) and cardiovascular disease (CVD). The present study aimed to investigate the association between serum klotho and cardiac parameters from a large-scale Korean CKD cohort.
Source: BackgroundAbstract: What methods does the paper describe?
We analyzed 2101 participants from KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) cohort who had been measured for serum klotho levels. Left ventricular hypertrophy evaluated by left ventricular mass index (LVMI) and arterial stiffness measured by brachial-to-ankle pulse wave velocity (baPWV) were explored as cardiovascular parameters.
Source: MethodsAbstract: Results
Patients were 53.6 ± 12.2 years old and 61.1% were male. The mean estimated glomerular filtration rate (eGFR) was 53.0 ± 30.7 mL/min/1.73m2. The median serum klotho level was 536 (interquartile range [IQR]: 420 to 667) pg/mL. Advanced CKD stages were associated with lower serum klotho levels (P < 0.001, P for linear trend < 0.001). Ascending quartiles of klotho were significantly associated with decreased LMVI (P < 0.001, P for linear trend< 0.001). A multivariable linear regression model showed serum klotho had a significant inverse association with LVMI (β − 0.04; 95% CI [confidence interval] -0.004, − 0.00007; P = 0.041).
However, there was no significant association between serum klotho and baPWV after adjustment (β 0.003; 95% CI -0.04, 0.05; P = 0.876).
Source: ResultsAbstract: Conclusions
Serum klotho was an independent biomarker of LVMI, but not arterial stiffness.
Source: ConclusionsAuthors’ abstract
Background
Klotho, a protein linked to aging, has emerged as a pivotal player in mineral bone metabolism and might explain the relationship between chronic kidney disease (CKD) and cardiovascular disease (CVD). The present study aimed to investigate the association between serum klotho and cardiac parameters from a large-scale Korean CKD cohort.
Methods
We analyzed 2101 participants from KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) cohort who had been measured for serum klotho levels. Left ventricular hypertrophy evaluated by left ventricular mass index (LVMI) and arterial stiffness measured by brachial-to-ankle pulse wave velocity (baPWV) were explored as cardiovascular parameters.
Results
Patients were 53.6 ± 12.2 years old and 61.1% were male. The mean estimated glomerular filtration rate (eGFR) was 53.0 ± 30.7 mL/min/1.73m2. The median serum klotho level was 536 (interquartile range [IQR]: 420 to 667) pg/mL. Advanced CKD stages were associated with lower serum klotho levels (P < 0.001, P for linear trend < 0.001). Ascending quartiles of klotho were significantly associated with decreased LMVI (P < 0.001, P for linear trend< 0.001). A multivariable linear regression model showed serum klotho had a significant inverse association with LVMI (β − 0.04; 95% CI [confidence interval] -0.004, − 0.00007; P = 0.041).
However, there was no significant association between serum klotho and baPWV after adjustment (β 0.003; 95% CI -0.04, 0.05; P = 0.876).
Trial registration
This trial was registered on ClinicalTrials.gov on 28 June 2012 (NCT01630486).
Conclusions
Serum klotho was an independent biomarker of LVMI, but not arterial stiffness.
Publication and source details
Original title: The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study
Hyo Jin Kim; Eunjeong Kang; Yun Kyu Oh; Yeong Hoon Kim; Seung Hyeok Han; Tae Hyun Yoo; Dong-Wan Chae; Joongyub Lee; Curie Ahn; Kook-Hwan Oh
BMC Nephrology · 2018
© The Author(s). 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.The Korea Center for Disease Control and Prevention2011E3300300, 2012E3301100, 2013E3301600, 2013E3301601, 2013E3301602, and 2016E3300200Ahn CurieRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T19:14:47.846192+00:00
DOI: 10.1186/s12882-018-0851-3 · PMC5838864